News
Source: NASDAQ
- EyePoint Pharmaceuticals Provides 2019 Commercial Update
- EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
- EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
- EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
- EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
- EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
- EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors
- EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
- EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
- EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
- EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
- EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors